Erasca (ERAS) Receivables - Other (2021 - 2022)
Erasca posted quarterly Receivables - Other of $100000.0 for Q3 2022, little changed on a QoQ basis from $100000.0 in Q2 2022.
Erasca (ERAS) has 2 years of Receivables - Other data on file, last reported at $100000.0 in Q3 2022.
- For the quarter ending Q3 2022, Receivables - Other changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Sep 2022 stood at $100000.0 (changed N/A YoY), and the FY2021 full-year result was $100000.0, changed N/A from the prior year.
- Receivables - Other for Q3 2022 stood at $100000.0, roughly flat from $100000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $100000.0 in Q4 2021 and bottomed at $100000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |